Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Molecular Biology Laboratory

Latest From European Molecular Biology Laboratory

Deals Shaping The Medical Industry, July-August 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device


Enterome will use its metagenomics platform to develop drugs that target the effects of alterations in the microbiota, and to identify, develop and commercialize biomarkers. The company's biomarkers will be used to develop diagnostics, and to stratify populations, identifying those most likely to respond to treatment. Enterome is focused on metabolic and bowel diseases, with lead projects in nonalcoholic steatohepatitis and in inflammatory bowel disease.

BioPharmaceutical Medical Device

Cenix BioScience GmbH

Cenix is equipped to do high-throughput, genome-scale RNAi screening. The firm believes that its infrastructure and expertise will allow it to help Big pharma and biotech partners sort through masses of targets to find those with biological relevance. Management believes its methodology can also contribute to drug development--RNAi could, for instance, act as a modifier in screening assays, to see whether this additional means of silencing a gene could improve a drug candidate's activity.
BioPharmaceutical Strategy

EMBLEM Technology Transfer GmbH

Five years ago, the Heidelberg, Germany-based European Molecular Biology Laboratory (EMBL) spun out its first company, Lion Bioscience AG. Since then, EMBL has signed 120 license agreements and created five start-up companies.
BioPharmaceutical Europe
See All